Jentadueto Patent Expiration

JENTADUETO's oppositions filed in EPO
JENTADUETO IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7407955 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
May, 2025

(9 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6303661 BOEHRINGER INGELHEIM Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals
Apr, 2017

(7 years ago)

US6890898 BOEHRINGER INGELHEIM Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US7078381 BOEHRINGER INGELHEIM Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US7459428 BOEHRINGER INGELHEIM Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US8178541 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(11 months ago)

US8119648 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(11 months ago)

US7407955

(Pediatric)

BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Nov, 2025

(1 year, 3 months from now)

US8883805 BOEHRINGER INGELHEIM Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
Nov, 2025

(1 year, 4 months from now)

US8883805

(Pediatric)

BOEHRINGER INGELHEIM Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
May, 2026

(1 year, 10 months from now)

US8673927 BOEHRINGER INGELHEIM Uses of DPP-IV inhibitors
May, 2027

(2 years from now)

US9173859 BOEHRINGER INGELHEIM Uses of DPP IV inhibitors
May, 2027

(2 years from now)

US8673927

(Pediatric)

BOEHRINGER INGELHEIM Uses of DPP-IV inhibitors
Nov, 2027

(3 years from now)

US9415016 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Apr, 2029

(4 years from now)

US10022379 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Apr, 2029

(4 years from now)

US10973827 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Apr, 2029

(4 years from now)

US9415016

(Pediatric)

BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Oct, 2029

(5 years from now)

US10022379

(Pediatric)

BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Oct, 2029

(5 years from now)

US10973827

(Pediatric)

BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Oct, 2029

(5 years from now)

US11911388 BOEHRINGER INGELHEIM Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
Apr, 2030

(5 years from now)

US9155705 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
May, 2030

(5 years from now)

US8846695 BOEHRINGER INGELHEIM Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor
Jun, 2030

(5 years from now)

US9155705

(Pediatric)

BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Nov, 2030

(6 years from now)

US8846695

(Pediatric)

BOEHRINGER INGELHEIM Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor
Dec, 2030

(6 years from now)



Jentadueto is a drug owned by Boehringer Ingelheim Pharmaceuticals Inc. It is used for treating type 2 diabetes mellitus. Jentadueto uses Linagliptin; Metformin Hydrochloride as an active ingredient. Jentadueto was launched by Boehringer Ingelheim in 2012. It is is available in tablet form for oral use. Its generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Dec 04, 2030 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Jan 30, 2015
New Chemical Entity Exclusivity(NCE) May 02, 2016
M(M-146) Jul 30, 2017
M(M-258) Jul 03, 2022
M(M-252) Mar 30, 2023
M(M-295) Jun 20, 2026
Pediatric Exclusivity(PED) Dec 20, 2026

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

NCE-1 date: 20 December, 2025

Market Authorisation Date: 30 January, 2012

Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in com...

Dosage: TABLET

How can I launch a generic of JENTADUETO before it's drug patent expiration?
More Information on Dosage

JENTADUETO family patents

Family Patents